Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis

News
Article

Tofacitinib is a novel JAK inhibitor, selective for JAK 1 and JAK 3.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
Related Content
driftwood-stock@adobe.com

Medicare Plans Face Higher Liability From Cap on Out-of-Pocket Drug Costs

Denise Myshko
August 15th 2025
Article

Read More

David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2

David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2

Briana Contreras
August 15th 2025
Podcast

Listen

Medication Prior Authorization Biggest Daily Challenge for 1 in 5 Prescribers, Survey Says

Medication Prior Authorization Biggest Daily Challenge for 1 in 5 Prescribers, Survey Says

Logan Lutton
August 15th 2025
Article

Read More

FDA Approves First Treatment for Chronic Inflammatory Lung Condition

FDA Approves First Treatment for Chronic Inflammatory Lung Condition

Denise Myshko
August 15th 2025
Article

Read More

FDA Approves Ajovy for Childhood Migraine Prevention

FDA Approves Ajovy for Childhood Migraine Prevention

Logan Lutton
August 15th 2025
Article

Read More

ZAKARIYAE-stock@adobe.com

FDA Grants Accelerated Approval For Targeted Drug for Rare Brain Tumor

Denise Myshko
August 15th 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.